A Phase 1/2 interventional study of Humanized anti-CD117 Monoclonal Antibody (JSP191) in SCID, sponsored by Jasper Therapeutics, Inc.. Terminated at 9 sites in United States. Open to participants aged 3 Months to 12 Years. Per ClinicalTrials.gov, last updated 2025-07-28.
Sponsored by Jasper Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Immunologic Deficiency Syndromes with a site in United States — 27 open to participants now, 34 under way, none of them phase 3. Immunologic Deficiency Syndromes · United States.
Among the 127 studies in Immunologic Deficiency Syndromes with a site in United States, this one is the 40th largest by enrollment of the 77 interventional ones that give a count, is one of 6 that started in 2017, is one of 11 in phase 1/2, and was the 87th registered.
204 studies on the registry are indexed under Immunologic Deficiency Syndromes; 50 are open to participants now.
Browse Immunologic Deficiency Syndromes studies →27 of the 127 studies in Immunologic Deficiency Syndromes with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 1–120 · Healthy volunteers
Henry M. Jackson Foundation for the Advancement of Military Medicine · Sites in United States
Ages 4+
Monica Bhatia · Sites in United States
Ages 3 mo–26 yrs
Children's Hospital of Philadelphia · Sites in United States
Ages 1 mo–25 yrs
Washington University School of Medicine · Sites in United States
Ages 8+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Immunologic Deficiency Syndromes studies recruiting now, 19 (44%) set no upper age limit and 14 (33%) stop at 75 or younger; 30 take children under 18; 10 take healthy volunteers.
This study: 3 Months to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 40 · Phase 3 10 · Phase 4 2
First in 1977; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 30 across 123 interventional studies indexed under Immunologic Deficiency Syndromes.
Median enrollment 28 across the 77 interventional studies, 142 across the 45 observational. Of the 83 that completed or were terminated, 28 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 127 have an industry lead sponsor. The 10 most frequent:
Jasper Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Jasper Therapeutics, Inc. has 1 study filed under Immunologic Deficiency Syndromes — fewer than ten, so there is no comparison to draw.
9 of the studies in Immunologic Deficiency Syndromes with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06689800Washington University School of MedicineLet's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy | 2026-11-30 |
| NCT02356653Children's Hospital of PhiladelphiaExpanded Access Protocol Using CD3+/CD19+ Depleted PBSC | 2027-01 |
| NCT05584488Columbia UniversityAllergy and Immunology Natural History Study | 2027-01 |
| NCT05333471National Institute of Allergy and Infectious Diseases (NIAID)Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis | 2027-03-01 |
| NCT04554914Pierre Fabre MedicamentA Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 127 studies in Immunologic Deficiency Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody conditioning regimen, known as JSP191, in patients with Severe Combined Immune Deficiency undergoing blood stem cell transplantation
A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody conditioning regimen, known as JSP191, in patients with SCID undergoing blood stem cell transplantation. Blood Stem Cell transplantation offers the only potentially curative therapy for SCID.
The biological conditioning regimen, JSP191, is an antibody that binds to CD117. CD117 is the receptor for Stem Cell Factor on blood forming cells. CD117 binding to Stem Cell Factor is critical for survival and maintenance of blood forming stem cells. The binding of JSP191 to CD117 blocks CD117 from binding to Stem Cell Factor on blood forming stem cells. In the absence of CD117/Stem Cell Factor binding, hematopoietic stem cells that are currently occupying the bone marrow niches in SCID patients exit from the bone marrow.
Key Inclusion Criteria:
Typical SCID as defined by Primary Immune Deficiency Treatment Consortia including but not limited to the following subtypes:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study will enroll two groups: Group A: previously transplanted SCID patients; Group B: newly diagnosed SCID. The study plans to assess JSP191 in different dose cohorts. Patients will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery.
Biological: Humanized anti-CD117 Monoclonal Antibody (JSP191)
Procedure: single intravenous infusion of JSP191 antibody
Phase 1: Safety and tolerability of JSP191 as conditioning therapy in SCID patients undergoing HCT: adverse events
The number of subjects experiencing dose limiting toxicities including adverse events and serious adverse events will be assessed.
Time frame: Up to 5 years post Donor Cell Transplant (28 days dose limiting toxicity period)
Phase 2: Efficacy of JSP191 as conditioning therapy in SCID patients
To enable engraftment of allogeneic CD34+ hematopoietic cells, as determined by CD15+ donor myeloid chimerism
Time frame: Up to 24 weeks post Donor Cell Transplant
Phase 2: Efficacy of JSP191 as conditioning therapy in SCID patients
To enable immune reconstitution, as determined by the production of naive T cells
Time frame: Weeks 36-104 post Donor Cell Transplant
Plan to share: No — Data collected is for future publication
No publications or documents are linked to this record.
Ran from Mar 2017 to primary completion in Jul 2025, 99 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Briquilimab
Immunologic Deficiency Syndromes →
Jasper Therapeutics, Inc.